In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Feature|Articles|July 9, 2026
Hematologists Detail Practice-Shaping Data That Emerged at EHA 2026 (VIDEO)
Author(s)Chris Ryan
Fact checked by: Riley Kandel
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Advertisement
Advertisement
Pivotal data shared across multiple myeloma, large B-cell lymphoma (LBCL), and myeloproliferative neoplasms (MPNs) took the spotlight during the
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
In a phase 1/2 study, the LSD1 inhibitor bomedemstat reduced spleen volume, improved symptoms, and lowered driver mutation burden in patients with advanced myelofibrosis.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Advertisement
Advertisement